预约演示
更新于：2026-06-06
GQ-1001
更新于：2026-06-06
概要
基本信息
药物类型 ADC |
别名 GQ 1001、GQ1001 |
作用方式 拮抗剂、抑制剂 |
作用机制 HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂)、微管蛋白抑制剂、ADCC(抗体依赖的细胞毒作用) |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 18481L
Sequence Code 44772H
关联
2
项与 GQ-1001 相关的临床试验NCT05575804
Phase Ib/II Study of GQ1001 and Pyrotinib in HER2 Positive Metastatic Breast Cancer Patients Who Had Failed Previous Anti-HER2 Treatment（GRACE）
NCT04450732
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
100 项与 GQ-1001 相关的临床结果
登录后查看更多信息
100 项与 GQ-1001 相关的转化医学
登录后查看更多信息
100 项与 GQ-1001 相关的专利（医药）
登录后查看更多信息
266
项与 GQ-1001 相关的文献（医药）2025-08-01BIOMEDICINE & PHARMACOTHERAPY
Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates
Article
作者: Kim, Yeongbeom ; Kim, Hongbin ; Park, Jeong-Ann ; Kim, Yihyeon ; Lim, Su Yeon ; Han, Seungmin ; Won, Young-Wook ; Yun, Jina ; Lim, Kwang Suk ; Yong, Seok-Beom
The combination of antibody-drug conjugates (ADCs) and immunotherapy has emerged as a promising strategy for cancer treatment. However, effective integration of chemotherapy and immunotherapy remains a challenge. Here, we introduce a universal surface-engineered NK (USE-NK) platform, which rapidly modifies immune cells into a targeted chemoimmunotherapy system by enabling the spontaneous incorporation of antibodies or ADCs. This platform utilizes a recombinant fusion protein (C3) derived from Protein G and a polymeric lipid-based conjugation strategy to stably attach therapeutic antibodies to NK cell surfaces without genetic modifications, preserving their native functionality. This approach enhances tumor targeting, minimizes off-target toxicity, and maintains NK cell cytotoxicity. Both in vitro and in vivo studies demonstrated that USE-NK conjugated with trastuzumab (TZ) or trastuzumab-emtansine (T-DM1) exhibited superior HER2-positive cancer cell recognition and cytotoxicity compared to NK cells treated with each agent separately. This enhancement was driven by the combined effects of 1) targeted delivery of potent chemotherapeutic agents with minimizing off-target toxicity, 2) enhanced mobilization of USE-NK toward tumor tissue, and 3) the cytotoxic activity of USE-NK against cancer cells. This rapid, non-invasive, and reversible engineering method provides a flexible approach to chemoimmunotherapy. Additionally, it extends beyond NK cells to other immune cell therapies, including CAR-T and CAR-NK cells. By leveraging the antibody-binding ability of C3, this platform enables multi-antigen targeting to address tumor heterogeneity. The scalability and adaptability of USE-NK position it as a promising candidate for personalized and off-the-shelf cancer immunotherapies.
2025-07-01ACS Nano
Membrane Fusion Drives Facile Uptake of Cell Membrane-Coated Nanocarriers
Article
作者: Alp, Yasin ; Qiu, Jingyi ; Thayumanavan, S. ; Medeiros, Jewel ; Gong, Shuai ; Agnello, Emily
Endocytosis has been the bane of the intracellular delivery efficiency of nanoscale systems. A class of delivery systems, viz., cell membrane-coated nanoparticles (CMNPs), show efficacious and even cell-selective uptake. We were interested in investigating the mechanism of interaction between cells and CMNPs, especially in the context of endocytic uptake and endosomal escape. We find that CMNPs are mainly taken up through a membrane-fusion-driven uptake pathway, bypassing endosomal entrapment and directly delivering therapeutic cargo to the cytoplasm. This fusion mechanism results in a significant enhancement in the intracellular delivery efficiency of both hydrophobic small molecules and nucleic acids as the cargo. The cargo-agnostic increase in delivery efficacy suggests a broad impact of this delivery system in diverse therapeutic areas.
2025-07-01Molecular Oncology
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients
Article
作者: Jirka Grosse ; Peter Ugocsai ; Wolfgang Dietmaier ; Michael Althammer ; Florian Weber ; Florian Lüke ; Tobias Pukrop ; Kamran Honarnejad ; Daniel Heudobler ; Nataša Stojanović Gužvić ; Anke Schlenska-Lange ; Katja Evert ; Christoph A. Klein ; Stephan Seitz ; Martin Hoffmann ; Thomas Schamberger ; Kathrin Weidele ; Christian Werno ; Xin Lu ; Jens Warfsmann ; Steffi Treitschke ; Ulrich Kaiser ; Bernhard Polzer ; Felix Keil ; Roman Mayr ; Christian Schulz ; Giancarlo Feliciello ; Catherine Botteron ; Dirk Hellwig ; Adithi Ravikumar Varadarajan ; Silvia Materna–Reichelt ; Andrea Coluccio
While cell‐free liquid biopsy (cfLB) approaches provide simple and inexpensive disease monitoring, cell‐based liquid biopsy (cLB) may enable additional molecular genetic assessment of systemic disease heterogeneity and preclinical model development. We investigated 71 blood samples of 62 patients with various advanced cancer types and subjected enriched circulating tumor cells (CTCs) to organoid culture conditions. CTC‐derived tumoroid models were characterized by DNA/RNA sequencing and immunohistochemistry, as well as functional drug testing. Results were linked to molecular features of primary tumors, metastases, and CTCs; CTC enumeration was linked to disease progression. Of 52 samples with positive CTC counts (≥1) from eight different cancer types, only CTCs from two salivary gland cancer (SGC) patients formed tumoroid cultures (P = 0.0005). Longitudinal CTC enumeration of one SGC patient closely reflected disease progression during treatment and revealed metastatic relapse earlier than clinical imaging. Multiomics analysis and functional in vitro drug testing identified potential resistance mechanisms and drug vulnerabilities. We conclude that cLB might add a functional dimension (to the genetic approaches) in the personalized management of rare, difficult‐to‐treat cancers such as SGC.
24
项与 GQ-1001 相关的新闻（医药）2026-02-09
临床申请siRNA抗体药物偶联物临床1期免疫疗法
2026-02-08
·信狐药迅
2026-02-02
·谈医说药
疫苗信使RNA申请上市临床1期核酸药物
100 项与 GQ-1001 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HER2阳性转移性乳腺癌 | 临床2期 | 中国 | 2022-10-01 | |
| 晚期恶性实体瘤 | 临床1期 | 美国 | 2020-07-07 | |
| 晚期恶性实体瘤 | 临床1期 | 中国 | 2020-07-07 | |
| 晚期恶性实体瘤 | 临床1期 | 澳大利亚 | 2020-07-07 | |
| HER2阳性胆道肿瘤 | 临床1期 | 美国 | 2020-07-07 | |
| HER2阳性胆道肿瘤 | 临床1期 | 中国 | 2020-07-07 | |
| HER2阳性胆道肿瘤 | 临床1期 | 澳大利亚 | 2020-07-07 | |
| HER2阳性乳腺癌 | 临床1期 | 美国 | 2020-07-07 | |
| HER2阳性乳腺癌 | 临床1期 | 澳大利亚 | 2020-07-07 | |
| HER2阳性唾液腺癌 | 临床1期 | 美国 | 2020-07-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | HER2阳性实体瘤 HER2 positive | 32 | 簾糧鹹齋遞鹹選憲餘鑰(窪鏇範構鏇壓窪壓選製) = 4/32, 12.5% 糧願製醖遞襯顧齋範鏇 (壓艱餘鑰廠構鑰齋網鹹 ) | 积极 | 2025-01-09 | ||
临床1期 | 15 | 鹹餘憲襯蓋廠鹹顧艱艱(醖醖鏇觸選積憲繭簾廠) = 憲製蓋顧醖築膚廠構願 繭鏇獵艱簾襯製襯衊繭 (製餘繭糧鏇築壓構壓鏇 ) | 积极 | 2024-11-26 | |||
鹹餘憲襯蓋廠鹹顧艱艱(醖醖鏇觸選積憲繭簾廠) = 遞憲網醖夢餘構遞積願 繭鏇獵艱簾襯製襯衊繭 (製餘繭糧鏇築壓構壓鏇 ) | |||||||
临床1期 | 15 | 艱鑰膚憲夢衊襯鏇構齋(獵鑰鹽夢製壓簾範觸窪) = 築構餘鹽襯鑰艱獵選築 遞顧衊鏇製鹹鏇艱廠製 (淵鹽簾積窪膚窪憲鏇糧 ) 更多 | 积极 | 2023-04-14 | |||
網鑰餘夢鬱糧鏇蓋簾願(網顧繭壓獵簾範遞膚製) = 鬱繭繭願壓積獵蓋網蓋 淵遞鬱顧鹽網醖鹽壓艱 (構齋鏇鑰衊鹽獵顧鑰顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用